Search

Author/Creator Sievert, Mark

1. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Issue 12 (December 2016)

Authors:
Al-Batran, Salah-Eddin; Hofheinz, Ralf D; Pauligk, Claudia; Kopp, Hans-Georg; Haag, Georg Martin; Luley, Kim Barbara; Meiler, Johannes; Homann, Nils; Lorenzen, Sylvie; Schmalenberg, Harald; Probst, Stephan; Koenigsmann, Michael; Egger, Matthias; Prasnikar, Nicole; Caca, Karel; Trojan, Jörg; Marte...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 12(2016:Dec.)
Page Start:
1697
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma. (1st February 2023)

Authors:
Richter, Joshua; Lin, Peggy L.; Garcia‐Horton, Viviana; Guyot, Patricia; Singh, Erin; Zhou, Zheng‐Yi; Sievert, Mark; Taiji, Riley
Journal:
Cancer medicine
Issue:
Volume 12:Number 7(2023)
Page Start:
8005
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search